Comparison of standard and accelerated corneal cross-linking for the treatment of keratoconus: a meta-analysis

Acta Ophthalmol. 2019 Feb;97(1):e22-e35. doi: 10.1111/aos.13814. Epub 2018 May 31.

Abstract

Purpose: To compare results between standard and accelerated corneal collagen cross-linking (CXL) for the treatment of progressive keratoconus.

Methods: We performed literature searches in PubMed, Cochrane Library, Web of Science, ISRCTN registry, ClinicalTrials.gov, and EMBASE for studies comparing conventional Dresden (C-CXL) and accelerated CXL (A-CXL). Outcomes were clinical results and changes in corneal properties. Weighted mean differences were used to evaluate the effects.

Results: Here, 22 studies with 1158 eyes (C-CXL: 577 eyes; A-CXL: 581 eyes) were included. At the last follow-up, C-CXL was superior regarding minimum keratometry (p < 0.00001) and demarcation line depth (p < 0.00001), whereas A-CXL should be favoured when considering minimum corneal thickness (p = 0.0005). No differences in uncorrected and corrected distance visual acuity (p = 0.09 and 0.98), spherical equivalent (p = 0.11), spherical and cylindrical error (p = 0.29 and 0.32), maximal and average keratometry (p = 0.05 and 0.65), central corneal thickness (p = 0.15), corneal biomechanical properties (p ≥ 0.21 respectively), time of reepithelialization (p = 0.76), subbasal nerve density (p = 0.69), endothelial cell density (p = 0.30) and morphology (p ≥ 0.40 respectively) were found among both groups.

Conclusion: Consideration of less corneal thinning favours A-CXL, whereas the deeper demarcation line and greater changes in minimum keratometric values in C-CXL may indicate a higher treatment efficacy. Altogether, C-CXL, as well as A-CXL, provides successful results in the strengthening of corneal tissue.

Keywords: accelerated cross-linking; corneal collagen cross-linking; different cross-linking protocols; progressive keratoconus; standard Dresden cross-linking.

Publication types

  • Meta-Analysis
  • Review

MeSH terms

  • Collagen / therapeutic use*
  • Cornea / pathology*
  • Corneal Topography
  • Cross-Linking Reagents / therapeutic use*
  • Humans
  • Keratoconus / drug therapy*
  • Keratoconus / pathology
  • Photochemotherapy / methods*
  • Photosensitizing Agents / therapeutic use
  • Riboflavin / therapeutic use*
  • Treatment Outcome
  • Visual Acuity*

Substances

  • Cross-Linking Reagents
  • Photosensitizing Agents
  • Collagen
  • Riboflavin